Liquid Biopsy for Cancer Detection and Monitoring
Exploratory findings from the VALENTINO trial, released on May 12, 2026, suggest a strong correlation between baseline ctDNA detection and early dynamics with clinical outcomes in metastatic colorectal cancer patients. As of May 2026, liquid biopsies are showing promise in various cancer care areas, including lung, colorectal, and B-cell lymphoma, with new trials launching for ctDNA-guided treatment in breast cancer and early diagnosis of EBV-positive Burkitt lymphoma. Researchers at Memorial Sloan Kettering Cancer Center developed a novel liquid biopsy technique using AI and nanosensors that detects brain tumors with 98% accuracy. The FDA granted Breakthrough Device Designation to the CatCHimera liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma, and Roche is acquiring SAGA Diagnostics' tumor-informed molecular residual disease (MRD) platform to strengthen cancer recurrence detection. While promising, a review in npj Precision Oncology on May 1, 2026, highlighted that age-related biological changes can complicate accuracy in older adults, requiring further research.
Timeline
Want updates on this thread?
Track this storyTimeline of developments
May 2026 — 2 developments
Exploratory findings from the VALENTINO trial suggest a strong correlation between baseline ctDNA de…
Exploratory findings from the VALENTINO trial suggest a strong correlation between baseline ctDNA detection and early dynamics with clinical outcomes in metastatic colorectal cancer patients. Additionally, ctDNA analysis shows potential to transform treatment decisions for advanced or metastatic breast cancer by identifying critical mutations and offering a dynamic assessment compared to tissue biopsies.
A review in npj Precision Oncology highlights that while liquid biopsies show promise for personaliz…
A review in npj Precision Oncology highlights that while liquid biopsies show promise for personalized cancer care in older adults, age-related biological changes like increased cell-free DNA and clonal hematopoiesis can complicate accuracy and potentially lead to false positives. Further research is needed to refine these tests for the geriatric population, though they offer a less invasive alternative to traditional tissue biopsies.
April 2026 — 21 developments
An FDA advisory committee voted against the new drug application for camizestrant, a treatment for advanced breast cancer with ESR1 mutations.
An FDA advisory committee voted against the new drug application for camizestrant, a treatment for advanced breast cancer with ESR1 mutations. Concurrently, liquid biopsies are showing promise in lung, colorectal, and B-cell lymphoma care, with new trials launching for ctDNA-guided treatment in breast cancer and early diagnosis of EBV-positive Burkitt lymphoma.
New liquid biopsy methods like 'Bridge Capture' are being developed to enhance sensitivity and coverage for clinical testing and treatment selection.
New liquid biopsy methods like 'Bridge Capture' are being developed to enhance sensitivity and coverage for clinical testing and treatment selection. Additionally, circulating tumor DNA (ctDNA) is being investigated for its utility in de-escalating treatment for older breast cancer patients, diagnosing conditions in resource-limited settings, and guiding chemo-free neoadjuvant therapy.
Researchers at Memorial Sloan Kettering Cancer Center have developed a novel liquid biopsy technique…
Researchers at Memorial Sloan Kettering Cancer Center have developed a novel liquid biopsy technique that uses artificial intelligence and nanosensors to detect brain tumors with 98% accuracy by analyzing proteins in the bloodstream. This method is significant as it bypasses the limitations of traditional DNA-focused liquid biopsies, which struggle to detect markers that do not easily cross the blood-brain barrier.
The FDA has granted Breakthrough Device Designation to the CatCHimera liquid biopsy platform for mon…
The FDA has granted Breakthrough Device Designation to the CatCHimera liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma, utilizing viral DNA markers. A study in Science Translational Medicine demonstrates that liquid biopsies can assess and predict immune response to immunotherapy in breast cancer patients. Additionally, a novel Epigenetic Instability Index (EII) liquid biopsy has been developed to detect early-stage lung and breast cancers with high accuracy by measuring DNA methylation patterns.
Immuneering Corporation presented new ctDNA data at the AACR Annual Meeting, indicating that acquire…
Immuneering Corporation presented new ctDNA data at the AACR Annual Meeting, indicating that acquired MAPK pathway alterations are rare in patients treated with atebimetinib, suggesting sustained clinical benefit. Additionally, CelLBxHealth and The Royal Marsden NHS Foundation Trust are collaborating on a study using CTC-DNA for advanced non-small cell lung cancer patients with uninformative ctDNA tests.
Roche is acquiring SAGA Diagnostics' tumor-informed molecular residual disease (MRD) platform, which will be integrated into Foundation Medicine's monitoring portfolio.
Roche is acquiring SAGA Diagnostics' tumor-informed molecular residual disease (MRD) platform, which will be integrated into Foundation Medicine's monitoring portfolio. This acquisition aims to strengthen capabilities in detecting and monitoring cancer recurrence.
Companies are developing multi-cancer early detection tests with expected commercial availability in…
Companies are developing multi-cancer early detection tests with expected commercial availability in the latter half of 2026, while artificial intelligence is being explored to interpret ctDNA data for tracking progression and early detection of resistance. Myriad Genetics is presenting data on its Precise MRD assay for treatment monitoring and surveillance, and SAGA Diagnostics will present data on its ultrasensitive Pathlight™ MRD test for ovarian and metastatic breast cancer.
NeoGenomics announced that its PanTracer LBx liquid biopsy test has received Medicare coverage, expanding access to comprehensive genomic profiling for patients.
NeoGenomics announced that its PanTracer LBx liquid biopsy test has received Medicare coverage, expanding access to comprehensive genomic profiling for patients. This development is part of broader advancements in liquid biopsy and ctDNA research for cancer detection, monitoring, and treatment guidance.
At AACR 2026, a sub-study of the NSABP B-59/GBG-96-GeparDouze Trial showed that ctDNA detection afte…
At AACR 2026, a sub-study of the NSABP B-59/GBG-96-GeparDouze Trial showed that ctDNA detection after neoadjuvant treatment predicts recurrence in early triple-negative breast cancer. Separately, results from the SERENA-6 trial indicate that switching therapy based on ctDNA-detected ESR1 mutations improves progression-free survival in advanced HR+/HER2- breast cancer patients. Research also indicates ctDNA levels correlate with outcomes in advanced prostate cancer monitoring.
The AACR Annual Meeting and the World Conference on Oncology, Liquid Biopsy & Biomarkers are showcas…
The AACR Annual Meeting and the World Conference on Oncology, Liquid Biopsy & Biomarkers are showcasing advancements in liquid biopsy and ctDNA research, including new diagnostic tools and therapeutic strategies. Mayo Clinic is discussing liquid biopsy's role in cancer detection, while SAGA Diagnostics is presenting data on its Pathlight MRD test for cancer monitoring.
Quest Diagnostics' Haystack MRD test is being implemented at City of Hope for clinical trial partici…
Quest Diagnostics' Haystack MRD test is being implemented at City of Hope for clinical trial participants with solid tumors to evaluate its role in guiding disease management and early recurrence detection. SAGA Diagnostics presented data at AACR 2026 on its Pathlight MRD test, showing ultrasensitive ctDNA detection for predicting patient outcomes in metastatic breast and ovarian cancers. Ultima Genomics also showcased its ppmSeq technology at AACR 2026, demonstrating low single-digit parts-per-million sensitivity for ctDNA detection.
A new low-cost blood test analyzing DNA methylation patterns has been developed to potentially detec…
A new low-cost blood test analyzing DNA methylation patterns has been developed to potentially detect multiple cancers, including early-stage ones, and identify their tissue of origin. Separately, a new study indicates that ctDNA positivity after definitive treatment strongly predicts relapse in locally advanced cervical cancer, with all recurrences occurring in ctDNA-positive patients.
Myriad Genetics is presenting new findings from its MONITOR-Breast study at the AACR Annual Meeting,…
Myriad Genetics is presenting new findings from its MONITOR-Breast study at the AACR Annual Meeting, characterizing ctDNA dynamics during neoadjuvant therapy for breast cancer and associating distinct ctDNA response patterns with pathological response. Ultima Genomics presented initial TRACERx MRD data showcasing the performance of its ppmSeq technology in detecting ultra-low levels of circulating tumor DNA.
Quest Diagnostics is advancing its Haystack MRD platform, a ctDNA-based test, for clinical trials to guide disease management in breast, colorectal, ovarian, and prostate cancers.
Quest Diagnostics is advancing its Haystack MRD platform, a ctDNA-based test, for clinical trials to guide disease management in breast, colorectal, ovarian, and prostate cancers. The CATE trial is investigating elacestrant, guided by liquid biopsy, in women with HR+/HER2- breast cancer at high risk for recurrence to detect and intervene in early signs of recurrence.
ctDNA analysis is increasingly driving treatment decisions and moving beyond academic settings, with protocols expected to undergo revision.
ctDNA analysis is increasingly driving treatment decisions and moving beyond academic settings, with protocols expected to undergo revision. Spain aims to become a global hub for biomedical innovation by progressively incorporating liquid biopsy into routine clinical care. Ultra-sensitive assays are crucial for isolating ctDNA for early detection of recurrence and therapy response monitoring.
Croatia's Institute for Personalised Medicine, ranked third globally for precision tumor testing, pl…
Croatia's Institute for Personalised Medicine, ranked third globally for precision tumor testing, plans to broaden its use of liquid biopsy techniques to enhance cancer diagnosis and treatment monitoring.
Invivoscribe has introduced the PrepQuant™ System, an integrated platform designed to standardize sample preparation for molecular testing, including liquid biopsies.
Invivoscribe has introduced the PrepQuant™ System, an integrated platform designed to standardize sample preparation for molecular testing, including liquid biopsies. Patient-reported outcomes from the SERENA-6 trial also support the combination of camizestrant with a CDK4/6 inhibitor for advanced breast cancer with ESR1 mutations, showing improved progression-free survival.
The FDA is reviewing camizestrant for earlier use in breast cancer treatment, based on SERENA-6 trial data.
The FDA is reviewing camizestrant for earlier use in breast cancer treatment, based on SERENA-6 trial data. Additionally, breakthrough therapy designation has been granted for plixorafenib for BRAF V600E-mutated high-grade glioma.
The SERENA-6 trial is now specified as focusing on patients with non-small cell lung cancer (NSCLC), investigating the efficacy of specific treatments.
The SERENA-6 trial is now specified as focusing on patients with non-small cell lung cancer (NSCLC), investigating the efficacy of specific treatments. Further details on the trial's agents, patient eligibility, and locations are available on clinicaltrials.gov.
The MethylScan technology, detailed in PNAS, enables cost-effective cell-free DNA methylome profiling for cancer detection by depleting healthy DNA.
The MethylScan technology, detailed in PNAS, enables cost-effective cell-free DNA methylome profiling for cancer detection by depleting healthy DNA. Post-neoadjuvant therapy ctDNA positivity in breast cancer is linked to a higher chance of relapse, underscoring ctDNA's role in monitoring treatment response. The SERENA-6 trial demonstrated improved progression-free survival for advanced breast cancer with ESR1 mutations by switching to camizestrant based on ctDNA detection. GRAIL's Galleri liquid biopsy continues to show value in early cancer detection, supported by revenue growth and expanding partnerships.
UCLA researchers have developed a new blood test called MethylScan that analyzes DNA methylation patterns to detect various cancers and liver conditions.
UCLA researchers have developed a new blood test called MethylScan that analyzes DNA methylation patterns to detect various cancers and liver conditions. This advancement is part of ongoing efforts to create cost-effective blood tests for early cancer detection and monitoring.
March 2026 — 3 developments
Researchers are exploring ctDNA for personalizing breast cancer treatment in older women and for guiding adjuvant strategies in colon cancer.
Researchers are exploring ctDNA for personalizing breast cancer treatment in older women and for guiding adjuvant strategies in colon cancer. A simple blood test using liquid biopsy shows promise for rapid diagnosis of Burkitt lymphoma in children in Africa. Natera's Signatera assay has demonstrated clinical utility in anal squamous cell carcinoma and locally advanced rectal cancer.
VolitionRx Limited has announced a breakthrough in liquid biopsy, becoming the first company to isol…
VolitionRx Limited has announced a breakthrough in liquid biopsy, becoming the first company to isolate and analyze over 99% pure circulating tumor-derived DNA (ctDNA) from blood plasma. Their novel 'Capture-Seq' method combines physical enrichment with bioinformatic filtering to overcome the challenge of DNA originating from healthy cells. This advancement addresses a key hurdle in cancer detection.
The PREDICT-DNA study indicates that ctDNA clearance or persistence is a superior prognostic marker …
The PREDICT-DNA study indicates that ctDNA clearance or persistence is a superior prognostic marker to pathologic complete response in HER2-positive or triple-negative breast cancer. New research also suggests protein biomarkers can complement ctDNA for early cancer detection, particularly for early-stage cancers where ctDNA shedding may be intermittent. Additionally, ctDNA assays show promise in bladder cancer for predicting recurrence risk and in advanced breast cancer for quantitative HER2 profiling to improve treatment outcome predictions.
February 2026 — 10 developments
The SERENA-6 trial demonstrated that switching to camizestrant upon ctDNA detection of ESR1 mutation…
The SERENA-6 trial demonstrated that switching to camizestrant upon ctDNA detection of ESR1 mutations significantly improves progression-free survival (PFS) in patients with HR+/HER2- advanced breast cancer. Personalis's NeXT Personal test has received Medicare coverage for lung cancer surveillance, and Natera's MRD test shows broad utility across lymphoma subtypes and validation for colorectal cancer.
Updated data from the phase-2 ELEVATE trial indicate that elacestrant, when combined with everolimus…
Updated data from the phase-2 ELEVATE trial indicate that elacestrant, when combined with everolimus or abemaciclib, improved progression-free survival (PFS) in patients with ER-positive, HER2-negative metastatic breast cancer, regardless of ESR1 mutation status. This suggests elacestrant's potential as a backbone for breast cancer combination regimens.
Recent advancements in liquid biopsy technology are enhancing precision medicine for colorectal canc…
Recent advancements in liquid biopsy technology are enhancing precision medicine for colorectal cancer by enabling real-time monitoring of tumor evolution through the analysis of circulating tumor DNA (ctDNA). This approach provides insights into tumor genetics without invasive tissue biopsies, aiding in the detection of resistance mutations and identification of therapeutic targets.
Friends of Cancer Research is building evidence to validate circulating tumor DNA (ctDNA) as an early endpoint in oncology clinical trials through its ctMoniTR project.
Friends of Cancer Research is building evidence to validate circulating tumor DNA (ctDNA) as an early endpoint in oncology clinical trials through its ctMoniTR project. This initiative aims to establish ctDNA as a reliable marker for treatment response, potentially accelerating drug development.
A phase 3b study published in Clinical Cancer Research found that early changes in circulating tumor…
A phase 3b study published in Clinical Cancer Research found that early changes in circulating tumor DNA (ctDNA) strongly predict progression-free survival (PFS) in postmenopausal patients with HR+/HER2− advanced breast cancer treated with first-line ribociclib plus letrozole. Early ctDNA clearance was associated with improved PFS, and patients without new ctDNA alterations during treatment had a lower risk of progression.
The CATE clinical trial has been launched to investigate the clinical utility of ctDNA-guided treatment in breast cancer, focusing on patients at risk for late recurrence.
The CATE clinical trial has been launched to investigate the clinical utility of ctDNA-guided treatment in breast cancer, focusing on patients at risk for late recurrence. This trial is a collaboration between Personalis, Inc. and Yale Cancer Center. A recent podcast episode also explored the broad potential of liquid biopsies and ctDNA in cancer detection, treatment guidance, and monitoring.
New studies published in The Journal of Clinical Oncology and by Guardant Health indicate that a cir…
New studies published in The Journal of Clinical Oncology and by Guardant Health indicate that a circulating tumor DNA (ctDNA) blood test, Guardant Reveal, can more accurately identify patients at high risk of colon cancer recurrence after surgery compared to current standard methods. These findings support the routine use of ctDNA testing in post-surgical colon cancer care.
Researchers at Johns Hopkins Kimmel Cancer Center developed a novel liquid biopsy method using the Epigenetic Instability Index (EII) for early-stage cancer detection.
Researchers at Johns Hopkins Kimmel Cancer Center developed a novel liquid biopsy method using the Epigenetic Instability Index (EII) for early-stage cancer detection. Additionally, Yale Medicine announced a Phase II trial (CATE) for ctDNA-guided adjuvant therapy in hormone receptor-positive, HER2-negative breast cancers.
The integration of molecular residual disease (MRD) testing using highly sensitive liquid biopsy tec…
The integration of molecular residual disease (MRD) testing using highly sensitive liquid biopsy techniques to detect ctDNA is transforming cancer care by providing earlier and more precise indicators of recurrence risk. Serial ctDNA measurements have been shown to significantly improve relapse prediction, as indicated by studies presented in 2026.
The phase 3 SERENA-6 trial demonstrated that using ctDNA monitoring to guide treatment changes improved progression-free survival (PFS) in advanced breast cancer patients.
The phase 3 SERENA-6 trial demonstrated that using ctDNA monitoring to guide treatment changes improved progression-free survival (PFS) in advanced breast cancer patients. Personalis' NeXT Personal assay received Medicare coverage for lung cancer surveillance, and FDA-approved MCED tests are set for Medicare coverage following a federal spending bill.
January 2026 — 4 developments
Multi-modal liquid biopsy tests, such as SPOT-MAS, are expected to be routinely used in Southeast As…
Multi-modal liquid biopsy tests, such as SPOT-MAS, are expected to be routinely used in Southeast Asian countries for screening high-risk populations, indicating growing global integration into routine healthcare.
A new liquid biopsy test is being studied to predict how well patients with advanced breast cancer w…
A new liquid biopsy test is being studied to predict how well patients with advanced breast cancer will respond to targeted therapies by analyzing circulating tumor DNA (ctDNA) for early feedback on treatment effectiveness. Additionally, the BLOODPAC Consortium has introduced consensus recommendations for standardized analytical validation protocols for tumor-informed ctDNA assays used to detect Molecular Residual Disease (MRD). These protocols offer a framework for essential performance metrics for ctDNA assays.
Guardant Health received FDA approval for Guardant360® CDx as a companion diagnostic for BRAFTOVI® c…
Guardant Health received FDA approval for Guardant360® CDx as a companion diagnostic for BRAFTOVI® combination in patients with BRAF V600E-mutant metastatic colorectal cancer, further expanding the clinical utility of liquid biopsies.
A new study published in Annals of Surgery indicates that postoperative ctDNA (MRD) is a strong predictor of recurrence in rectal cancer patients with stage II-III disease.
A new study published in Annals of Surgery indicates that postoperative ctDNA (MRD) is a strong predictor of recurrence in rectal cancer patients with stage II-III disease. The study found that ctDNA-negative patients did not benefit from adjuvant chemotherapy, whereas ctDNA-positive patients showed significant benefit.
December 2025 — 1 developments
The SERENA-6 trial has demonstrated that switching to camizestrant based on molecular guidance signi…
The SERENA-6 trial has demonstrated that switching to camizestrant based on molecular guidance significantly improves progression-free survival for patients with HR+/HER2- advanced breast cancer who have ESR1 mutations. The study indicated a 54% reduction in the risk of death when using camizestrant.
November 2025 — 1 developments
The SERENA-6 trial demonstrated that switching to camizestrant plus a CDK4/6 inhibitor upon detectin…
The SERENA-6 trial demonstrated that switching to camizestrant plus a CDK4/6 inhibitor upon detecting ESR1 mutations in ctDNA significantly improved progression-free survival in breast cancer patients. Additionally, a company is developing liquid biopsy blood tests, such as mDETECT, that analyze DNA fragments to monitor cancer progression, offering a cost-effective method for real-time treatment feedback.
October 2025 — 1 developments
New patient-reported outcome data from the SERENA-6 trial, presented at the 2025 ESMO Congress, furt…
New patient-reported outcome data from the SERENA-6 trial, presented at the 2025 ESMO Congress, further support switching to camizestrant for patients with HR+/HER2- advanced breast cancer and emergent ESR1 mutations, showing a consistent benefit in delaying time to deterioration. Separately, the NeXT Personal assay has demonstrated that ctDNA dynamics correlate with better treatment response and survival across 24 tumor types, with ongoing developments in detecting ctDNA in surgical drain fluid for molecular residual disease detection.
September 2025 — 2 developments
Researchers at Mass General Brigham developed HPV-DeepSeek, a new liquid biopsy tool capable of detecting HPV-associated head and neck cancers up to a decade before symptoms appear.
Researchers at Mass General Brigham developed HPV-DeepSeek, a new liquid biopsy tool capable of detecting HPV-associated head and neck cancers up to a decade before symptoms appear. This study was published in the Journal of the National Cancer Institute.
Personalis, Inc.
Personalis, Inc. has launched the CATE clinical trial, a phase II study in collaboration with Yale Cancer Center, to investigate ctDNA-guided adjuvant therapy with elacestrant in hormone receptor-positive, HER2-negative breast cancers at risk for late recurrence. The trial will use the ultrasensitive Personalis NeXT Personal® test to detect the earliest molecular signs of recurrence before standard imaging. This aims to improve outcomes by enabling earlier intervention.
June 2025 — 2 developments
The phase 3 SERENA-6 trial demonstrated that using circulating tumor DNA (ctDNA) monitoring to guide…
The phase 3 SERENA-6 trial demonstrated that using circulating tumor DNA (ctDNA) monitoring to guide treatment changes before clinical progression significantly improved progression-free survival in patients with advanced breast cancer. An early switch to camizestrant upon ctDNA detection of ESR1 mutations resulted in a median PFS of 16.0 months compared to 9.2 months in the control group. The CATE clinical trial has also been launched to further explore the clinical utility of ctDNA-guided treatment in breast cancer.
The SERENA-6 Phase 3 trial demonstrated that using liquid biopsies to detect treatment-resistance mu…
The SERENA-6 Phase 3 trial demonstrated that using liquid biopsies to detect treatment-resistance mutations in advanced breast cancer, followed by a treatment change with camizestrant, significantly prolongs tumor control. This marks the first worldwide demonstration of clinical benefit for liquid biopsies in guiding treatment for hormone receptors-positive metastatic breast cancer.
April 2025 — 1 developments
Pilot projects are underway in England and Wales to evaluate the use of ctDNA-based liquid biopsies …
Pilot projects are underway in England and Wales to evaluate the use of ctDNA-based liquid biopsies for accelerating lung cancer treatment and improving access to targeted therapies. These initiatives aim to assess the economic implications and potential for enhanced patient outcomes compared to standard care.
June 2024 — 1 developments
Researchers have developed MRD-EDGE, an ultrasensitive liquid biopsy technology that uses whole-geno…
Researchers have developed MRD-EDGE, an ultrasensitive liquid biopsy technology that uses whole-genome sequencing and machine learning to detect cancer earlier than standard methods. This technology can distinguish cancer patterns from noise in blood samples.
January 2024 — 1 developments
The global liquid biopsy market for early cancer detection and monitoring was valued at USD 2.
The global liquid biopsy market for early cancer detection and monitoring was valued at USD 2.18 billion, reflecting significant commercial growth and investment in the technology.
February 2023 — 1 developments
BLOODPAC published a roadmap for early cancer detection and screening using liquid biopsy, outlining challenges and strategies for overcoming barriers to widespread adoption.
BLOODPAC published a roadmap for early cancer detection and screening using liquid biopsy, outlining challenges and strategies for overcoming barriers to widespread adoption.
January 2020 — 1 developments
The FDA approved the first blood tests (liquid biopsies) to identify cancer-related genetic changes by scanning DNA that tumors have shed into the blood.
The FDA approved the first blood tests (liquid biopsies) to identify cancer-related genetic changes by scanning DNA that tumors have shed into the blood. A study published in the Annals of Oncology also demonstrated that a liquid biopsy test could detect over 50 types of cancer, often before symptoms appeared.
January 2016 — 1 developments
The FDA approved the first circulating tumor DNA (ctDNA) blood-based genetic test, the cobas EGFR Mu…
The FDA approved the first circulating tumor DNA (ctDNA) blood-based genetic test, the cobas EGFR Mutation Test v2, for detecting epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC).
January 2013 — 1 developments
The U.S. Food and Drug Administration (FDA) approved the first liquid biopsy test, the CellSearch® C…
The U.S. Food and Drug Administration (FDA) approved the first liquid biopsy test, the CellSearch® CTC enumeration platform, for monitoring patients with advanced metastatic breast, colon, and prostate cancers.
January 2010 — 1 developments
The term 'liquid biopsy' was coined for the first time by Catherine Alix-Panabières and Klaus Pantel in a review exploring the challenges and opportunities of CTCs in cancer.
The term 'liquid biopsy' was coined for the first time by Catherine Alix-Panabières and Klaus Pantel in a review exploring the challenges and opportunities of CTCs in cancer.
January 2008 — 1 developments
BEAMing technology further verified that dynamic changes in circulating tumor DNA (ctDNA) could reflect tumor burden.
BEAMing technology further verified that dynamic changes in circulating tumor DNA (ctDNA) could reflect tumor burden.
January 2005 — 1 developments
Circulating Tumor Cells (CTCs) were proven to be an important indicator for predicting the survival of breast cancer patients, highlighting their diagnostic relevance.
Circulating Tumor Cells (CTCs) were proven to be an important indicator for predicting the survival of breast cancer patients, highlighting their diagnostic relevance.
January 1994 — 1 developments
Researchers unequivocally proved that cell-free nucleic acids found in the blood were derived from tumor tissues, based on the presence of characteristic cancer mutations.
Researchers unequivocally proved that cell-free nucleic acids found in the blood were derived from tumor tissues, based on the presence of characteristic cancer mutations.
January 1977 — 1 developments
Researchers made the novel observation that cancer patients carried cell-free DNA (cfDNA) in their peripheral blood.
Researchers made the novel observation that cancer patients carried cell-free DNA (cfDNA) in their peripheral blood.